Systemic sclerosis & Raynaud's
Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease
Authors' conclusion
In conclusion, cFAP does not seem useful as a biomarker in SSc-ILD.
Study context
- Population
- Patients with systemic sclerosis (SSc) with and without ILD; Circulating FAP (cFAP) measured in plasma by ELISA
- Participants
- 210 patients
- Exposure
- SSc with ILD vs SSc without ILD
- SSc-ILDn = 63
- SSc without ILDn = 147reference
- Outcome
- cFAP concentrations in baseline and repeated longitudinal samples, SSc with vs without ILD
- Follow-up
- Baseline and
Methodological detailslongitudinal, exploratory analysis of clinical features and all-cause mortality
- Longitudinal
- Exploratory analysis of clinical features and all-cause mortality
Main finding
As reported in the abstract
Baseline cFAP
P = 0.80
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Baseline cFAP by skin score (mRSS ≥ 10 vs mRSS < 10)cFAP elevated with higher skin scores | P = 0.01 |
cFAP at baseline and ILD progression · 1, 2 and 5 years
- No association between baseline cFAP and ILD progression
cFAP and all-cause mortality · 5 and 10 years
- No association between cFAP and all-cause mortality
Original publication
Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease. Arthritis Res Ther. Published 29 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →